摘要T细胞免疫疗法作为一种创新的治疗手段，通过激活患者自身的免疫系统，实现精准的抗肿瘤作用，从而改善患者预后。随着多款T细胞免疫疗法在全球范围内获批上市，该疗法在侵袭性B细胞淋巴瘤领域的应用日益广泛，但关于其临床规范应用尚无相关共识。因此，中国临床肿瘤学会（CSCO）淋巴瘤专家委员会结合循证医学证据和临床应用经验，讨论制定了T细胞免疫疗法治疗侵袭性B细胞淋巴瘤中国专家共识，旨在为我国医师临床规范化用药提供指导和建议。

abstractsAs an innovative treatment, T-cell immunotherapy can activate the patient's own immune system to achieve precise anti-tumor effects, and improve the prognosis of patients. With the worldwide approval of multiple T-cell immunotherapies, it has increasingly been applied in aggressive B-cell lymphoma treatment. However, there is currently no relevant consensus on its standardized clinical application. By referring to evidence-based medical evidence and clinical application experience, the Lymphoma Expert Committee of Chinese Society of Clinical Oncology (CSCO) discussed and formulated the Chinese expert consensus on T-cell immunotherapy in treatment of aggressive B-cell lymphoma, aiming to provide standardized medication guidance and suggestions for the Chinese clinicians.